UPDATE: Aldeyra Therapeutics (ALDX) PT Raised to 'Street High' $35 at Canaccord Genuity
(Updated - September 26, 2018 11:35 AM EDT)
(updated to add analyst comment)
Canaccord Genuity analyst John Newman raised the price target on Aldeyra Therapeutics (NASDAQ: ALDX) to a 'Street High' $35.00 (from $27.00) while maintaining a Buy rating.
The analyst comments "We are maintaining our BUY rating and raising our NPV-derived price target to $35 from $27, based on our expectation for positive Phase 3 dry eye data given the statistically significant improvement across all selected symptom and signs metrics seen in Phase 2b. Furthermore, we continue to expect positive Phase 3 data in allergic conjunctivitis YE18/early 2019, and also positive Phase 3 data in SLS and anterior noninfectious uveitis in 2019."